Fig. 4

Inhibition of Egr activity prevents Arecoline induced fibroblast proliferation. a Human oral fibroblasts were treated with 8 μg/ml Arecoline, Wnt1, Wnt2 or Wnt5a sepecific siRNAs for indicated times, then cell proliferation rate was quantified. b Human oral fibroblasts were transfected with Wnt5a promoter luciferase reporter plasmids, treated with 8 μg/ml Arecoline, 2 μM Mithramycin A (MMA) or 1 μM Chromomycin A3 (CHA) for indicated times, then luciferase reporter assays were performed to detect the activity of Wnt5a promoter. c-d Human oral fibroblasts were treated with 8 μg/ml Arecoline, 2 μM MMA or 1 μM CHA for indicated times, then RT-PCR assays were performed to detect the mRNA levels of Wnt5a (c) or cell proliferation rate was quantified (d). * denotes p < 0.05